Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease

A post hoc analysis of the AIM-HIGH trial

Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) Investigators

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background Metabolic syndrome (MS) is a well-known risk factor for the development of cardiovascular (CV) disease; yet, controversy persists whether it adds incremental prognostic value in patients with established CV disease. Objectives This study was performed to determine if MS is associated with worse CV outcomes in patients with established CV disease treated intensively with statins. Methods We performed a post hoc analysis of the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes trial, in which patients with established CV disease and atherogenic dyslipidemia (n = 3414) were randomly assigned to receive extended release niacin or placebo during a mean 36-month follow-up, to assess whether the presence of MS or the number of MS components contributed to CV outcomes. Results The composite primary end point of CV events occurred in 15.1% of patients without MS vs 13.8%, 16.9%, and 16.8% of patients with MS in the subsets with 3, 4, and 5 MS components, respectively (corresponding adjusted hazard ratios 0.9, 1.1, and 1.1 relative to patients without MS), P =.55. Comparing subgroups with 3 vs 4 or 5 MS components, there was no significant difference in either the composite primary end point or secondary end points. Patients with diabetes mellitus had higher event rates, with or without the presence of MS. Conclusions The presence of MS was not associated with worse CV outcomes in the AIM-HIGH population. The rate of CV events in statin-treated Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes patients with MS was not significantly influenced by the number of MS components.

Original languageEnglish (US)
Pages (from-to)1201-1211
Number of pages11
JournalJournal of Clinical Lipidology
Volume11
Issue number5
DOIs
StatePublished - Sep 1 2017

Fingerprint

Cardiovascular Diseases
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Triglycerides
Niacin
Dyslipidemias
Diabetes Mellitus
Placebos

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine

Cite this

Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) Investigators (2017). Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial. Journal of Clinical Lipidology, 11(5), 1201-1211. https://doi.org/10.1016/j.jacl.2017.06.017

Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease : A post hoc analysis of the AIM-HIGH trial. / Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) Investigators.

In: Journal of Clinical Lipidology, Vol. 11, No. 5, 01.09.2017, p. 1201-1211.

Research output: Contribution to journalArticle

Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) Investigators 2017, 'Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial', Journal of Clinical Lipidology, vol. 11, no. 5, pp. 1201-1211. https://doi.org/10.1016/j.jacl.2017.06.017
Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) Investigators. Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial. Journal of Clinical Lipidology. 2017 Sep 1;11(5):1201-1211. https://doi.org/10.1016/j.jacl.2017.06.017
Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) Investigators. / Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease : A post hoc analysis of the AIM-HIGH trial. In: Journal of Clinical Lipidology. 2017 ; Vol. 11, No. 5. pp. 1201-1211.
@article{9d19deaab49c4aeda75dcba3414c5a87,
title = "Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial",
abstract = "Background Metabolic syndrome (MS) is a well-known risk factor for the development of cardiovascular (CV) disease; yet, controversy persists whether it adds incremental prognostic value in patients with established CV disease. Objectives This study was performed to determine if MS is associated with worse CV outcomes in patients with established CV disease treated intensively with statins. Methods We performed a post hoc analysis of the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes trial, in which patients with established CV disease and atherogenic dyslipidemia (n = 3414) were randomly assigned to receive extended release niacin or placebo during a mean 36-month follow-up, to assess whether the presence of MS or the number of MS components contributed to CV outcomes. Results The composite primary end point of CV events occurred in 15.1{\%} of patients without MS vs 13.8{\%}, 16.9{\%}, and 16.8{\%} of patients with MS in the subsets with 3, 4, and 5 MS components, respectively (corresponding adjusted hazard ratios 0.9, 1.1, and 1.1 relative to patients without MS), P =.55. Comparing subgroups with 3 vs 4 or 5 MS components, there was no significant difference in either the composite primary end point or secondary end points. Patients with diabetes mellitus had higher event rates, with or without the presence of MS. Conclusions The presence of MS was not associated with worse CV outcomes in the AIM-HIGH population. The rate of CV events in statin-treated Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes patients with MS was not significantly influenced by the number of MS components.",
author = "{Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) Investigators} and Radmila Lyubarova and Robinson, {Jennifer G.} and Michael Miller and Simmons, {Debra L.} and Ping Xu and Abramson, {Beth L.} and Elam, {Marshall B.} and Brown, {Todd M.} and Marshall Elam and Fleg, {Jerome L.} and Patrice Desvigne-Nickens and Woubeshet Ayenew and Boden, {William E.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.jacl.2017.06.017",
language = "English (US)",
volume = "11",
pages = "1201--1211",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease

T2 - A post hoc analysis of the AIM-HIGH trial

AU - Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) Investigators

AU - Lyubarova, Radmila

AU - Robinson, Jennifer G.

AU - Miller, Michael

AU - Simmons, Debra L.

AU - Xu, Ping

AU - Abramson, Beth L.

AU - Elam, Marshall B.

AU - Brown, Todd M.

AU - Elam, Marshall

AU - Fleg, Jerome L.

AU - Desvigne-Nickens, Patrice

AU - Ayenew, Woubeshet

AU - Boden, William E.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background Metabolic syndrome (MS) is a well-known risk factor for the development of cardiovascular (CV) disease; yet, controversy persists whether it adds incremental prognostic value in patients with established CV disease. Objectives This study was performed to determine if MS is associated with worse CV outcomes in patients with established CV disease treated intensively with statins. Methods We performed a post hoc analysis of the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes trial, in which patients with established CV disease and atherogenic dyslipidemia (n = 3414) were randomly assigned to receive extended release niacin or placebo during a mean 36-month follow-up, to assess whether the presence of MS or the number of MS components contributed to CV outcomes. Results The composite primary end point of CV events occurred in 15.1% of patients without MS vs 13.8%, 16.9%, and 16.8% of patients with MS in the subsets with 3, 4, and 5 MS components, respectively (corresponding adjusted hazard ratios 0.9, 1.1, and 1.1 relative to patients without MS), P =.55. Comparing subgroups with 3 vs 4 or 5 MS components, there was no significant difference in either the composite primary end point or secondary end points. Patients with diabetes mellitus had higher event rates, with or without the presence of MS. Conclusions The presence of MS was not associated with worse CV outcomes in the AIM-HIGH population. The rate of CV events in statin-treated Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes patients with MS was not significantly influenced by the number of MS components.

AB - Background Metabolic syndrome (MS) is a well-known risk factor for the development of cardiovascular (CV) disease; yet, controversy persists whether it adds incremental prognostic value in patients with established CV disease. Objectives This study was performed to determine if MS is associated with worse CV outcomes in patients with established CV disease treated intensively with statins. Methods We performed a post hoc analysis of the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes trial, in which patients with established CV disease and atherogenic dyslipidemia (n = 3414) were randomly assigned to receive extended release niacin or placebo during a mean 36-month follow-up, to assess whether the presence of MS or the number of MS components contributed to CV outcomes. Results The composite primary end point of CV events occurred in 15.1% of patients without MS vs 13.8%, 16.9%, and 16.8% of patients with MS in the subsets with 3, 4, and 5 MS components, respectively (corresponding adjusted hazard ratios 0.9, 1.1, and 1.1 relative to patients without MS), P =.55. Comparing subgroups with 3 vs 4 or 5 MS components, there was no significant difference in either the composite primary end point or secondary end points. Patients with diabetes mellitus had higher event rates, with or without the presence of MS. Conclusions The presence of MS was not associated with worse CV outcomes in the AIM-HIGH population. The rate of CV events in statin-treated Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes patients with MS was not significantly influenced by the number of MS components.

UR - http://www.scopus.com/inward/record.url?scp=85028317648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028317648&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2017.06.017

DO - 10.1016/j.jacl.2017.06.017

M3 - Article

VL - 11

SP - 1201

EP - 1211

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

IS - 5

ER -